Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City
March 27, 2025
BioUtah member, Denali Therapeutics, yesterday celebrated the grand opening of its new state-of-the-art manufacturing facility in Salt Lake City. Denali is using deep scientific and drug development expertise to discover and deliver effective biologic therapeutics to the brain.
Co-founder and CEO, Ryan Watts, addressed the crowd who gathered to share the milestone with colleagues, public officials, and other guests. Watts talked about how Denali’s vision to fight neurodegenerative disease is much like the Utah pioneers who defied the odds to put down roots, build, and ultimately thrive in the state.
Other speakers included Governor Spencer Cox, Salt Lake City Mayor Erin Mendenhall, Cindy Dunkle, Chief People Officer for Denali, and Leah Frautschy, VP of Clinical Operations for Denali.
“With a team of experienced and passionate scientists and professionals, Denali is not only creating an economic footprint in Utah but its visionary research and drug development is poised to change the lives of so many patients and their families,” said Kelvyn Cullimore, president and CEO of BioUtah who was on hand to recognize the ambitious project’s opening. “We welcome Denali to Utah.”
Governor Spencer Cox and Salt Lake City Mayor, Erin Mendenhall also provided remarks. In applauding the launch of the Denali facility, Cox said, “It’s time to innovate and build here [in Utah].
Recent News
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
- Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
- Growing collaboration with New York Kidney & Hypertension Medicine
- CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease